Replies to post #75130 on Biotech Values

[DewDiligence]

Re: ACHN IDIX / HCV-protease selectivity

Is ACHN's claim of >4000 fold selectivity against human proteases akin to saying "no inhibition" of human proteases, or otherwise close?

This is the message they are attempting to convey, but I would take not the 4,000 figure too literally. We’ll know how selective ACH-1625 is for the HCV protease vs host proteases when we see the clinical data on side effects. Ditto for IDIX’s slide that asserts no inhibition of host proteases by IDX136/316.

I'm just curious how many proteases there are in total.

I don’t know the answer, but it’s many more than eight.